Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCHOLAR-2: Safety of Continuing HER-2 Therapy in LV Dysfunction
NCT04680442Phase 2Recruiting
- Sponsor
- Population Health Research Institute
- Start
- Jul 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 3
01
Overview
A Phase 2 trial of trastuzumab, pertuzumab, trastuzumab emtansine in breast cancer, sponsored by Population Health Research Institute. Started Jul 2021; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04680442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680442.